Services

Our services are centred around intellectual property that can be registered. We protect innovation, design, and branding across all sectors of industry, and at all stages in the supply chain.

For each IP right we offer services covering strategic advice, pre-registration searches, registrations and renewals, oppositions and dispute resolution. We handle work throughout the world, working with local colleagues in over 100 countries.

Sectors

Our attorneys specialise in one or more sectors of industry, which enables them to provide quality advice with a commercial focus.

Our patent specialists have detailed understanding of the background technology, which ensures that your patent applications are prepared with the correct scope, reducing the likelihood of challenges from third parties and objections from the patent office.

They also advise whether other forms of protection would be more appropriate. Our brand specialists work with brand managers for leading brands and their advice is commercially focussed making sure that you get the best value from your budget.

23rd Jan 2020

What does the US-China trade deal mean for pharmaceutical patent holders?

On Wednesday 15th January 2020, US president Donald Trump and Chinese vice-premier Liu He signed an economic and trade agreement which Mr Trump described as “the biggest deal anybody has even seen”. The deal promises to be the first phase of a larger new trade agreement between the US and China, signifying a de-escalation in their trade war – at least for now. Intellectual property (IP) was one of the main points of contention during the trade talks and thus it is perhaps unsurprising that IP matters are addressed in the first chapter. Of particular interest to those in the pharmaceutical sector will be Sections C and D of Chapter 1, which outline China’s commitment to improving protection and enforcement of pharmaceutical related patent rights. Sceptics will argue that these provisions simply represent a long overdue pledge by China to align its patent system with the US and other Western states, with no guarantee that they will actually implement or enforce the provisions of the agreement. However, in my view the deal appears to represent China’s willingness to do more to protect pharmaceutical patent rights and contains provisions that (if properly implemented and enforced) could significantly increase the value of drug related patents in China.

22nd Jan 2020

READY… OR MAYBE NOT QUITE YET?

The EPO says they’d be ready to get going with Unitary Patents later this year. Has anyone else spotted the (Br)elephant in the room? According to a press release published by the European Patent Office (EPO) on 10th January 2020, the EPO president António Campinos and his team have recently met with the Chair of the EPO Unitary Patent (UP) Select Committee and members of the Unified Patent Court (UPC) Preparatory Committee from the EU member states. The main item on the agenda for them was a discussion of the most recent developments concerning the implementation of UP and UPC (the so called Unitary Patent package, which we have talked about here).

21st Jan 2020

Vertical axis wind turbines – Good enough to blow away the competition?

Whether you like it or not, the UK is a windy place. It is therefore not surprising that wind accounted for more than 50% of the electricity generated from renewable energy sources in 2019[1]. Modern energy generation wind turbines can come in many forms, in this blog I will discuss vertical axis wind turbines (VAWTs) which are becoming a larger part of the wind renewable energy market.

Register for notifications
Enter your email address here to receive our monthly bulletin of IP news and developments.
    Please read our privacy notice.
Saved Staff
Staff member

Remove all

Saved profiles
Call +44 (0)20 7242 0901
Call +44 (0)1223 360 350
Call +49 (0) 89 206054 267
Call +(00) 31 70 800 2162